Market Research Report
Global In Situ Hybridization Market Size study, By Technology, By Probe Type, By Product By Application, By End-use and Regional Forecasts 2021-2027
|Global In Situ Hybridization Market Size study, By Technology, By Probe Type, By Product By Application, By End-use and Regional Forecasts 2021-2027|
Published: January 8, 2022
Bizwit Research & Consulting LLP
Delivery time: 2-3 business days
Global In Situ Hybridization Market is valued approximately at USD 1,333.5 million in 2020 and is anticipated to grow with a healthy growth rate of more than 8.9% over the forecast period 2021-2027. In Situ Hybridization is a technique that allows for precise localization of a specific segment of nucleic acid. It is used in cancer, cytogenetics, development biology, infectious diseases, and others. The increasing cases of cancer is expected to lead to the adoption of In Situ Hybridization across the forecast period. For Instance: according to American Cancer Society in 2020, the number of cancer cases are increasing rapidly . According to World Health Organization in 2020, 2.26 million breast cancer cases were estimated. The cases of lung, colon and prostate cancer are also growing rapidly. According To American Cancer Society in 2018, there were 17.0 million cancer cases globally which is estimated to reach approximately 27.5 million cases by 2040. Rising demand for molecular diagnostic tools anticipating the market growth of in situ hybridization Also, with the technological advancement and introduction of advanced probe-based technologies, the adoption & demand for In Situ Hybridization is likely to increase the market growth during the forecast period. However, high cost of in situ hybridization impedes the growth of the market over the forecast period of 2021-2027.
The geographical regions considered for the global In Situ Hybridization market analysis include Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is dominating the market as the leading region across the world in terms of largest revenue share due to the growing healthcare expenditure, increasing number of patients. Whereas, Asia-Pacific is also estimated to attain maximum growth rate during 2021-2027. Factors such rising research and development activities and improving healthcare infrastructure would create beneficial growth scenario for the In Situ Hybridization market across Asia-Pacific region.
Major market player included in this report are:
Leica Biosystems Nussloch GmbH
Thermo Fisher Scientific
NeoGenomics Laboratories, Inc.
Bio-Rad Laboratories, Inc.
Oxford Gene Technology
Advanced Cell Diagnostics, Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
Fluorescent In Situ Hybridization
Chromogenic In Situ Hybridization
Kits & Probes
Hospitals & Diagnostic Laboratories
Academic& Research Institutes
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027
Target Audience of the Global In Situ Hybridization Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Value-Added Resellers (VARs)
Third-party knowledge providers
List of figures